Bruton’s tyrosine kinase inhibitors such as ibrutinib have significantly improved outcomes for chronic lymphocytic leukemia, ...

Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-313 clinical trial of Jaypirca ...

Researchers at the University of Eastern Finland and their international collaborators have identified key developmental and molecular differences between the two main subtypes of chronic lymphocytic ...

A number of recent trials have explored potential strategies for using immunotherapy in chronic lymphocytic leukemia (CLL). The authors explained that while molecularly targeted therapies like Bruton ...

Objective response rate (ORR) of 83% including two complete responses in CLL patients in Phase 1a study with median progression free survival ...

SAN FRANCISCO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of ...

SAN FRANCISCO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of ...

Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company specializing in protein degradation therapies, has been making waves in the biotechnology sector with its innovative approach to ...

SEATTLE and FORT MYERS, Fla., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (ADPT), a commercial stage biotechnology company that aims to translate the genetics of the ...